Pseudomonas bacteremia precipitated by ticlopidine-induced neutropenia

Annals of Pharmacotherapy

Volumn 30, Issue 3, 1996, Pages 246-248

  Geletko, Sandra M ^a,b   Melbourne, Kathleen M ^c,d   Mikolich, Dennis J ^e  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF RHODE ISLAND   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^e BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0029913124     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603000307     Document Type: Article

References (14)

1. Olin BR, ed Drug facts and comparisons. St Louis: Facts and Comparisons, 1995.
2. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;1:1215-20.
3. Hass WK, Easton JD, Adams HP, Pyrse-Phillips W, Molony BA, Anderson S. et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients N Engl J Med 1989;321:501-7.
4. Janzon L, Bergqvist D, Boberg J, Boberg M, Eriksson I, Lindgarde F, et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication: effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med 1990;227:301-8.
5. McTavish D, Faulds D, Goa KL. Ticlopidine: an updated review of its pharmacology and therapeutic use in platelet-dependent disorders. Drugs 1990;40:238-59.
6. Haynes RB, Sandier RS, Larson EB, Pater JL, Yatsu FM. A critical appraisal of ticlopidine, a new antiplatelet agent. Effectiveness and clinical indications for prophylaxis of atherosclerotic events. Arch Intern Med 1992;152:1376-80.
7. Ono K, Kurohara K, Yoshihara M, Shimamoto Y, Yamaguchi M. Agranulocytosis caused by ticlopidine and its mechanism. Am J Hematol 1991;37:239-42.
8. Guerciolini R, Giordano G, Aversa F, Del Favero A. Anaemia and agranulocytosis associated with ticlopidine therapy, Acta Haematol 1985,73:232-4.
9. Farver DK, Hansen LA. Delayed neutropenia with ticlopidine. Ann Pharmacother 1994;28:1344-6.
10. Khelif A, Assouline D, Ffrench M, Chaumentin G, Viala JJ. Ticlopidine and aplastic anaemia, Br J Haematol 1993;83:678-9.
11. Carlson JA, Maesner JE. Fatal neutropenia and thrombocytopenia associated with ticlopidine. Ann Pharmacother 1994;28:1236-8.
12. Nand S, Bayer R, Prinz RA, Felten W, Godwin JE. Granulocytemacrophage colony stimulating factor for the treatment of drug induced agranulocytosis. Am J Hematol 1991;37:267-9.
13. Ruiz-Irastorza G, Alonso JJ, Iglesias JJ, Aguirre C. Granulocyte colonystimulating factor for neutropenia secondary to ticlopidine. Acta Haematol 1994;91:106-7.
14. Elis A, Lishner M, Lang R, Ravid M. Agranulocytosis associated with enalapril. DICP Ann Pharmacother 1991;25.461-2.